dc.contributor.advisor | Meier, P | |
dc.contributor.author | Jamal, K | |
dc.contributor.editor | Meier, P | |
dc.date.accessioned | 2019-11-27T14:04:37Z | |
dc.date.issued | 2019-11-30 | |
dc.identifier.citation | 2019 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3431 | |
dc.description.abstract | Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project is to understand how TNF (Tumour Necrosis Factor), a master pro-inflammatory cytokine can cause "immunogenic" cell death. This death is dependent on activation of Receptor Interacting Protein Kinase 1 (RIPK1). Therefore, it is pivotal to understand how this kinase is regulated by a variety of checkpoints, which ensure that TNF stimulation induces NFkB signalling, inflammation and cell survival. However, the perturbation of these checkpoints induces TNF dependent cell death. Here, I have characterised the mechanism by which the E3 ubiquitin ligase Mind-Bomb-2 (MIB2) regulates TNF-induced cell death by inactivating RIPK1 via inhibitory ubiquitylation. While depletion of MIB2 has little effect on NFkB activation, it sensitises cells to RIPK1- and caspase-8-dependent cell death. I find that MIB2 represses the cytotoxic potential of RIPK1 by ubiquitylating RIPK1 at specific lysines, thereby interfering with RIPK1's oligomerisation and RIPK1-FADD association. Together, my findings demonstrate that Mind Bomb 3 ubiquitin-ligases can function as additional checkpoints of TNF-induced cell death, selectively protecting cells from the cytotoxic effects of TNF. Furthermore, I have used a clinically relevant animal model to evaluate the therapeutic advantage of inducing RIPK1 dependent cell death. I have shown that Sma Mimetics (SM) (IAP degraders) augment the efficacy of the standard of care (SOC) treatment of extremity malignancies. Mechanistically, combination treatment with SOC/SM promotes RIPK1-mediated cell death, which significantly improves local disease control, increases infiltration/activation of CD8+ T cells and NK cells, and enhances the survival benefit of immune checkpoint blockade. My findings warrant a clinical trial to assess the survival benefit of RIPK1-induced immunogenic cell death in patients with advanced disease at limb extremities. | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Institute of Cancer Research (University Of London) | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | Targeting RIPK1 ubiquitylation to promote anti-tumour immunity | |
dc.type | Thesis or Dissertation | |
dcterms.accessRights | Public | |
dcterms.license | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-11-30 | |
rioxxterms.type | Thesis | |
pubs.notes | 6 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity | |
pubs.embargo.terms | 6 months | |
icr.researchteam | Cell Death and Immunity | en_US |
dc.contributor.icrauthor | Jamal, Kunzah | |
uketdterms.institution | Institute of Cancer Research | |
uketdterms.qualificationlevel | Doctoral | |
uketdterms.qualificationname | Ph.D | |
dc.type.qualificationlevel | Doctoral | |
dc.type.qualificationname | Ph.D | |